LAG-3, TIM-3 & TIGIT Checkpoint Pipeline — PatSnap Eureka
LAG-3, TIM-3 & TIGIT Checkpoint Inhibitor Pipeline in Solid Tumors & Hematologic Malignancies
The next-generation immune checkpoints LAG-3, TIM-3, and TIGIT have emerged as priority therapeutic targets driven by the incomplete response rates of approved PD-1/PD-L1 and CTLA-4 inhibitors. Explore the patent intelligence, clinical signals, and combination strategies shaping this rapidly maturing pipeline.
Three Next-Generation Checkpoints — One Converging Rationale
Co-expression of LAG-3, TIM-3, and TIGIT with PD-1 on tumor-infiltrating lymphocytes drives deeper T cell exhaustion and poorer patient outcomes, establishing the mechanistic basis for next-generation combination strategies.
LAG-3: T Cell Suppression via MHC-II and FGL1
LAG-3 is a type I transmembrane protein expressed on activated CD4+ and CD8+ T cells, NK cells, and dendritic cells. Its primary ligands include MHC class II, fibrinogen-like protein 1 (FGL1), LSECtin, and Galectin-3. LAG-3 suppresses T cell proliferation and cytokine production — notably IL-2 and IFN-γ — upon ligand engagement. FGL1 is expressed on tumor cell surfaces in breast cancer and in the cytoplasm in NSCLC, making it a key non-MHC-II ligand in the tumor microenvironment.
High LAG-3/FGL1 co-expression → immune suppression & enhanced tumor growthTIM-3: Leukemic Stem Cell Vulnerability in AML/MDS
TIM-3 is expressed on dysfunctional T cells, NK cells, dendritic cells, and — critically — on leukemic stem cells in AML, a feature distinguishing it from LAG-3 and TIGIT. Ligands include phosphatidylserine (PtdSer), Galectin-9, CEACAM1, and HMGB1. This enables three mechanistic dimensions: canonical checkpoint inhibition, modulation of leukemic stem cell self-renewal, and antibody-dependent phagocytosis of TIM-3-expressing leukemic cells — making TIM-3 mechanistically distinct in the AML/MDS context.
TIM-3 on leukemic stem cells → unique AML/MDS targetTIGIT: Competitive Suppression of CD226 Activating Signal
TIGIT is an inhibitory receptor expressed on activated T cells, NK cells, and regulatory T cells (Tregs). It binds CD155 (PVR) and CD112 (PVRL2/Nectin-2) on tumor cells and antigen-presenting cells. TIGIT competitively outbinds CD226 (DNAM-1) for PVR, suppressing T and NK cell responses. In AML, PVR and PVRL2 overexpression on leukemic cells independently correlates with inferior outcomes across two patient cohorts, providing a tumor-intrinsic rationale for TIGIT blockade strategies.
TIGIT outcompetes CD226 for PVR → T/NK cell suppressionCo-Expression of Multiple Checkpoints Drives Deeper Exhaustion
The core biological rationale shared across sources is that T cell exhaustion in the tumor microenvironment is not mediated by a single inhibitory pathway. Co-expression of LAG-3/PD-1, TIM-3/PD-1, and TIGIT/PD-1 is associated with deeper functional impairment and poorer patient outcomes. PD-1 blockade upregulates TIM-3 as a compensatory mechanism in head and neck squamous cell carcinoma, providing a mechanistic basis for sequential or co-administered next-generation checkpoint combinations in patients progressing on existing PD-1 therapies.
PD-1 blockade upregulates TIM-3 → resistance mechanismClinical Development & Modality Landscape
Patent and literature data reveal the development stage distribution, therapeutic modality mix, and key clinical signals across LAG-3, TIM-3, and TIGIT programs.
Development Stage by Checkpoint Target
LAG-3 leads with regulatory approval; TIM-3 and TIGIT are advancing through Phase I–III across solid tumors and hematologic malignancies.
Therapeutic Modality Distribution
Monoclonal antibodies dominate the pipeline across all three targets; bispecifics and small molecules represent emerging differentiated approaches.
From First-in-Class mAbs to Bispecifics and Small Molecules
The dominant LAG-3 modality across retrieved results is the antagonistic monoclonal antibody, with relatlimab (BMS-986016) most prominently cited. The combination of nivolumab (anti-PD-1) + relatlimab (anti-LAG-3) — commercialized as Opdualag — received FDA approval for unresectable or metastatic melanoma, representing the first approved LAG-3 inhibitor combination. Retrieved data state that this combination "more than doubled" progression-free survival relative to nivolumab monotherapy. According to published clinical literature, 19 LAG-3 targeting molecules are being evaluated across 108 clinical trials.
For TIM-3, sabatolimab (MBG453, Novartis) is the most clinically advanced agent in this dataset, evaluated in AML and MDS in combination with hypomethylating agents (HMAs). Sabatolimab induces responses through immune checkpoint blockade, modulation of leukemic stem cell self-renewal, and antibody-dependent phagocytosis — three non-redundant mechanisms. EMD Serono's M6903 is a fully human, effector-functionless anti-TIM-3 antibody that blocks TIM-3 binding to PtdSer, CEACAM1, and Galectin-9 simultaneously. Yale University data describe durable responses in higher-risk MDS and AML in early clinical trials, with randomized trials currently ongoing.
For TIGIT, BeiGene-affiliated data report 5 anti-TIGIT molecules in Phase II or above as of 2021. In AML, antibody blockade of TIGIT's ligands PVR and PVRL2, or TIGIT blockade on immune cells, increased anti-leukemic cytolytic activity — including synergy with the BiTE construct AMG 330. An emerging small-molecule approach via GSK-3α/β inhibition downregulates LAG-3 expression on CD4+ and CD8+ T cells, with GSK-3 SMIs outperforming LAG-3 antibody blockade alone in a B16 melanoma preclinical model. This represents an indirect, transcriptional mechanism of LAG-3 suppression distinct from direct receptor blockade — relevant to small-molecule immuno-oncology programs. Learn more about the broader immune checkpoint biology at NIH.
Convergent Signals Pointing to Combination-Centric Development
Retrieved results reveal multiple convergent combination strategies across LAG-3, TIM-3, and TIGIT programs — from established backbone doublets to trimodal regimens and bispecific co-blockade.
LAG-3 + PD-1: Established Backbone
The LAG-3/PD-1 co-blockade combination is the most evidence-supported pairing in this dataset — supported by BMS patents explicitly claiming this combination, Regeneron patents claiming the same, and multiple academic publications documenting preclinical synergy and clinical trial data. A new generation of bispecific PD-1/LAG-3 blocking agents with "strong capacities to specifically target PD-1+ LAG-3+ highly exhausted T cells" is described in retrieved Navarrabiomed literature.
LAG-3 + PD-1 + Chemotherapy (Gastric/GEJ)
BMS patents specifically extend the LAG-3 + PD-1 combination to include chemotherapy in gastric and gastroesophageal junction cancer patients, signaling an indication-specific trimodal strategy. Retrieved EP, IL, and SG patent families reflect active prosecution of this combination method claim across multiple jurisdictions. Drug developers should anticipate freedom-to-operate constraints in this indication space.
TIM-3 + PD-1: Bispecific & Sequential
University of Basel data characterize ex vivo tumor responses to PD1-TIM3 bispecific antibodies using multicolor flow cytometry, scRNA-seq, and multiplex analysis — demonstrating differential molecular and cellular effects compared to anti-PD-1 monotherapy. TIM-3 compensatory upregulation after PD-1 blockade in HNSCC tumor-infiltrating lymphocytes further supports combined targeting. TIM-3 is also proposed as a target in HCC, where PD-1 inhibitors are already approved, via life sciences IP intelligence.
TIGIT + PD-1: Most Actively Pursued Clinical Combination
High TIGIT expression correlates with inferior overall survival (HR = 1.42, 95% CI: 1.11–1.82) in solid cancers, and dual TIGIT/PD-1 blockade is the primary therapeutic strategy proposed. Co-expression of PD-1 and TIGIT on circulating CD8+ T cells in melanoma patients was identified as a baseline biomarker predictive of response to PD-1 inhibition. In GBM, anti-PD-1 + anti-TIGIT dual therapy significantly improved survival in a murine GL261-luc+ model, with increased effector T cell function and Treg downregulation.
Who Holds the Dominant Checkpoint Inhibitor IP Positions?
Commercial IP is concentrated at a smaller number of entities while mechanistic and biomarker research is academically driven — a pattern consistent across the LAG-3, TIM-3, and TIGIT field.
| Assignee | Target(s) | Activity Type | Key Signal | Jurisdictions |
|---|---|---|---|---|
| Bristol-Myers Squibb | LAG-3 | Patent | 5+ filings: LAG-3+ tumor treatment & LAG-3+PD-1+chemo in gastric/GEJ cancer | EP (active 2023), IL, SG |
| Regeneron Pharmaceuticals | LAG-3 + PD-1 | Patent | 2 patents: PD-1 + LAG-3 inhibitor combination methods | IL, SG (2021) |
| Idera Pharmaceuticals | Multi-checkpoint | Patent | TLR9 agonist + checkpoint inhibitor; intratumoral delivery (2 patents, both inactive) | IL (2017, 2022) |
| Genentech / Roche | TIGIT | Literature | TIGIT-CD226-PVR axis characterization; biomarker development in atezolizumab trials | — |
| EMD Serono (Merck KGaA) | TIM-3 | Literature | M6903 anti-TIM-3 mAb: blocks PtdSer, CEACAM1, Gal-9 simultaneously | — |
| Janssen Pharmaceuticals | TIM-3 + TIGIT | Literature | Anti-TIM-3 or anti-TIGIT + anti-PD-1 in adoptive T cell transfer models in NSCLC | — |
| Academic Institutions | LAG-3, TIM-3, TIGIT | Literature | Navarrabiomed, U. Basel, U. Pittsburgh, Johns Hopkins, Yale, MD Anderson, BeiGene, Hamburg-Eppendorf + more | Global |
Map freedom-to-operate risks across LAG-3 combination methods
PatSnap Eureka surfaces BMS, Regeneron, and Idera IP across EP, IL, and SG jurisdictions in seconds. Explore the full patent analytics platform or review customer case studies.
Key Evidence Across Solid Tumors and Hematologic Malignancies
From FDA approval in melanoma to Phase I/II signals in AML/MDS and preclinical GBM data — the clinical evidence base for next-generation checkpoints spans multiple tumor types.
Tumor Type Coverage by Checkpoint Target
Evidence density across tumor types documented in retrieved patent and literature records for LAG-3, TIM-3, and TIGIT programs.
TIGIT Expression & Overall Survival — Solid Cancers
High TIGIT expression correlates with inferior overall survival (HR = 1.42, 95% CI: 1.11–1.82) in solid cancers, supporting dual TIGIT/PD-1 blockade as a therapeutic strategy.
What the Patent & Literature Dataset Signals for Drug Developers
BMS holds the dominant LAG-3 IP position in this dataset, with multiple active and pending patents across EP, IL, and SG jurisdictions covering LAG-3-positive tumor treatment methods and LAG-3 + PD-1 + chemotherapy combinations. Regeneron represents a significant second entrant in this specific combination IP space. Drug developers and IP strategists should anticipate freedom-to-operate constraints around combination methods involving anti-LAG-3 + anti-PD-1 antibodies, particularly for gastric/GEJ and melanoma indications. The European Patent Office EP family (active status, 2023) reflects ongoing prosecution.
TIM-3 is the most differentiated checkpoint in hematologic malignancies among the three targets. Its expression on leukemic stem cells enables mechanistically distinct therapeutic modalities — antibody-dependent phagocytosis and stem cell self-renewal modulation — beyond canonical T cell checkpoint restoration. This positions TIM-3 inhibitors (particularly sabatolimab-class agents) as uniquely suited for AML/MDS combination regimens with hypomethylating agents, rather than classical anti-PD-1 doublets. Explore life sciences IP solutions for AML program support.
TIGIT's PVR/CD155-CD226 competitive binding axis creates a targetable vulnerability across both solid tumors and AML, with ligand overexpression on tumor cells serving as a companion biomarker opportunity. The TNBC (n=243 surgically resected samples) and AML data suggest that TIGIT/PVR immunohistochemistry or transcriptomic profiling could support patient stratification strategies in future clinical programs. The FDA has not yet approved any TIGIT-targeting agent, underscoring the opportunity window for developers. Bispecific antibodies targeting PD-1/LAG-3 and PD-1/TIM-3 simultaneously represent an emerging modality with differentiated mechanistic evidence — ex vivo tumor characterization studies provide translational tools (scRNA-seq, multiplex cytokine analysis) to define responsive tumor microenvironments. Access the PatSnap API for programmatic biomarker data integration.
LAG-3, TIM-3 & TIGIT Checkpoint Inhibitors — Key Questions Answered
LAG-3, TIM-3, and TIGIT are the three most clinically advanced next-generation immune checkpoint receptors following PD-1 and CTLA-4. T cell exhaustion in the tumor microenvironment is not mediated by a single inhibitory pathway, and co-expression of multiple inhibitory receptors — particularly LAG-3/PD-1, TIM-3/PD-1, and TIGIT/PD-1 — is associated with deeper functional impairment and poorer patient outcomes.
Yes. The combination of nivolumab (anti-PD-1) and relatlimab (anti-LAG-3) — commercialized as Opdualag — received FDA approval for unresectable or metastatic melanoma, representing the first approved LAG-3 inhibitor combination. This combination more than doubled progression-free survival relative to nivolumab monotherapy.
TIM-3 is expressed on leukemic stem cells in AML, a feature that distinguishes its biology from LAG-3 and TIGIT. This enables mechanistically distinct therapeutic modalities including antibody-dependent phagocytosis of TIM-3-expressing leukemic cells and modulation of leukemic stem cell self-renewal — beyond canonical T cell checkpoint restoration. Sabatolimab (MBG453, Novartis) has demonstrated durable responses in higher-risk MDS and AML in early clinical trials in combination with hypomethylating agents.
TIGIT and CD96 transmit inhibitory signals, while CD226 (DNAM-1) transmits activating signals upon binding the same ligands PVR (CD155) and PVRL2 (CD112). TIGIT competitively outbinds CD226 for PVR, thereby suppressing T and NK cell responses. In AML, PVR and PVRL2 overexpression on leukemic cells correlates with poor outcomes, providing a tumor-intrinsic rationale for TIGIT blockade.
Bristol-Myers Squibb is the single most active patent assignee in this dataset, with at least 5 distinct patent filings across SG, IL, and EP jurisdictions covering treatment of LAG-3-positive tumors and LAG-3 combination therapy for gastric and gastroesophageal junction cancer. Regeneron Pharmaceuticals represents a significant second entrant, with two patents covering PD-1 inhibitor and LAG-3 inhibitor combination methods in IL and SG jurisdictions.
The LAG-3/PD-1 co-blockade combination is the most evidence-supported pairing, supported by BMS and Regeneron patents and multiple academic publications. TIM-3 is being combined with PD-1 via bispecific antibodies and sequentially after PD-1 blockade. TIGIT/PD-1 dual blockade is the most actively pursued TIGIT combination clinically, with high TIGIT expression correlating with inferior overall survival (HR = 1.42, 95% CI: 1.11–1.82) in solid cancers. In AML, TIGIT/PVR blockade may synergize with T cell-redirecting bispecific constructs such as AMG 330.
Still have questions? Let PatSnap Eureka search the checkpoint inhibitor patent and literature database for you.
Ask Eureka About Checkpoint InhibitorsAccelerate Your Next-Generation Checkpoint Inhibitor Research
Join 18,000+ innovators already using PatSnap Eureka to map the LAG-3, TIM-3, and TIGIT patent landscape, identify combination strategy IP risks, and surface clinical signals across AML, NSCLC, melanoma, and beyond.
References
- Immune Checkpoint LAG3 and Its Ligand FGL1 in Cancer — Tangdu Hospital, Air Force Medical University (2022)
- The promising immune checkpoint LAG-3 in cancer immunotherapy: from basic research to clinical application — First Affiliated Hospital, Zhengzhou University (2022)
- LAG-3 as a Potent Target for Novel Anticancer Therapies of a Wide Range of Tumors — Wroclaw Medical University (2022)
- Cutting-Edge: Preclinical and Clinical Development of the First Approved LAG-3 Inhibitor — Navarrabiomed-Fundación Miguel Servet, UPNA/HUN/IdiSNA (2022)
- TIM-3: a tumor-associated antigen beyond checkpoint inhibition? — University of Cape Town (2022)
- Identification and characterization of M6903, an antagonistic anti-TIM-3 monoclonal antibody — EMD Serono Research and Development Institute (2020)
- Immune Checkpoint Inhibition in Acute Myeloid Leukemia and Myelodysplastic Syndromes — Yale University (2022)
- TIGIT-CD226-PVR axis: advancing immune checkpoint blockade for cancer immunotherapy — Genentech Inc (2022)
- Hitting the complexity of the TIGIT-CD96-CD112R-CD226 axis for next-generation cancer immunotherapy — Korea Institute of Science and Technology (2021)
- Immune checkpoints PVR and PVRL2 are prognostic markers in AML and their blockade represents a new therapeutic option — University Medical Center Hamburg-Eppendorf (2018)
- Deciphering molecular and cellular ex vivo responses to bispecific antibodies PD1-TIM3 and PD1-LAG3 in human tumors — University Hospital Basel (2022)
- Small Molecule Inhibition of GSK-3 Specifically Inhibits the Transcription of Inhibitory Co-receptor LAG-3 for Enhanced Anti-tumor Immunity — University of Cambridge (2020)
- Correlation of the TIGIT-PVR immune checkpoint axis with clinicopathological features in triple-negative breast cancer — Montpellier Cancer Institute Val d'Aurelle (2022)
- TIGIT and PD-1 Immune Checkpoint Pathways Are Associated With Patient Outcome and Anti-Tumor Immunity in Glioblastoma — University of Pittsburgh
- Targeting TIGIT for Immunotherapy of Cancer: Update on Clinical Development — BeiGene USA (2021)
- National Center for Biotechnology Information (NCBI) — PubMed checkpoint inhibitor literature database
- European Patent Office (EPO) — LAG-3 and checkpoint combination patent prosecution records
- U.S. Food and Drug Administration (FDA) — Opdualag (nivolumab + relatlimab) approval documentation
All data and statistics on this page are sourced from the references above and from PatSnap's proprietary innovation intelligence platform. This report is derived from a limited set of patent and literature records retrieved across targeted searches and represents a snapshot of innovation signals within this dataset only.
PatSnap Eureka searches patents and research to answer instantly.